Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6months or older and \>=5kg~* Sickle cell clinic attendant~* Both males and females~* Agree to abide by the study protocol~* Give informed consent and assent~* Not acutely sick at the time of recruitment~* Not having additional chronic disease~* Hb genotype of SS and SC confirmed by electrophoresis~Exclusion Criteria:~* known allergy to any of the antimalarial drugs use in the trial,~* severe illnesses requiring urgent admission,~* treatment with sulfadoxine-pyrimethamine or mefloquine in the previous 2wks~* patients on cotrimoxazole prophylaxis

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Daily proguanil (Type: ACTIVE_COMPARATOR): Standard policy of a supply of proguanil tablets to be taken daily
- IPT with MQ+AS bimonthly (Type: EXPERIMENTAL): Intermittent Preventive Treatment (IPT) consisting of a bimonthly course of treatment with mefloquine-artesunate (MQ+AS)
- IPT with SP+AQ bimonthly (Type: EXPERIMENTAL): IPT with bimonthly course of treatment with sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ)

Based on this trial design, predict the completion outcome and termination type (if applicable).